- 10x Genomics reported Q3 2026 revenue of US$150.67 million with a smaller quarterly net loss, raised full year 2026 revenue guidance, and continued to invest in AI powered products such as Sentira Single Cell.
- The combination of higher revenue guidance, early traction for Atera and Sentira, and ongoing losses highlights how 10x Genomics is relying on AI driven tools and consumables to support growth while still working toward a clear route to profitability.
- We will look at how 10x Genomics' investment narrative is reshaped by raised 2026 guidance backed by AI centric product momentum.
Scan beyond 10x Genomics and evaluate other AI focused lab-technology and data-platform players by reviewing the hand picked 36 healthcare AI stocks that could benefit from similar momentum in research workflows.
10x Genomics Investment Narrative Recap
To own 10x Genomics, you need to believe that demand for single cell, spatial and AI enabled analysis tools can support consistent top line progress while the business gradually narrows losses. The analyst consensus Narrative on Simply Wall St already expects revenue to grow, but not as fast as the wider US market. The Q3 update, with modest quarterly revenue growth and a smaller loss, points to some operating discipline without yet resolving the profitability question.
In the short term, the key swing factor remains how quickly new platforms like Atera and Sentira convert into recurring consumables and software usage. The raised 2026 revenue guidance suggests management sees enough order flow to offset funding headwinds and instrument discounting, although the larger year to date loss and ongoing pricing pressure in instruments keep execution risk elevated.
The launch of Sentira Single Cell is the most relevant recent announcement for this earnings story because it links the AI message directly to practical usage of 10x Genomics' Chromium data. Sentira gives researchers a natural language interface and agentic analysis on 10x Cloud, tied to Anthropic's Claude models, which could deepen engagement with existing installs.
For catalysts, Sentira Single Cell adds another way to drive compute and software revenue on top of consumables, while keeping scientists inside the 10x ecosystem as their datasets grow. The risk is that uptake or usage intensity falls short of expectations, which would limit the impact on margins and delay any shift from hardware driven sales toward more recurring, higher quality revenue streams.
10x Genomics' analyst narrative points to US$808.4 million in revenue and US$133.3 million in earnings by 2029, based on 9.4% yearly revenue growth and an earnings swing of about US$208.4 million from a current loss of US$75.1 million to the projected profit level.
Uncover why 10x Genomics' fair value indicates a 23% potential upside to its current price that may not last much longer.
Exploring Other Perspectives
One bullish twist on 10x Genomics hinges on Atera consumables pull through. The most optimistic analysts were already working off revenue reaching about US$864.7 million and earnings of roughly US$124.6 million by 2029. That is far above the consensus base case, so the latest guidance hike and Sentira launch could lead to those projections being revisited.
Explore 3 other 10x Genomics fair value estimates, including one that suggests as much as 51% upside from the current price.
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own research and judgment.
- A great starting point for your 10x Genomics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
- See our latest analysis for 10x Genomics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate 10x Genomics' overall financial position at a glance.
Looking for more investment ideas beyond 10x Genomics?
If the 10x Genomics story has sharpened your thinking about risk, cash runway and product traction, the next step is to widen your watchlist using targeted filters on the Simply Wall St Screener. That way you can compare this stock against other candidates that better match your preferences on value, resilience or income.
- If you are hunting for mispriced opportunities with quality fundamentals, start by scanning a curated set of 35 high quality undervalued stocks that already clear basic balance sheet and cash flow checks.
- For investors who care most about resilience through different market conditions, focus on a 30 resilient stocks with low risk scores that screens for businesses with sturdier financial profiles and fewer red flags.
- If you would rather back under-the-radar stories before they attract broad attention, use a 20 high quality undiscovered gems built around smaller, fundamentally sound companies that often slip past headline-driven screens.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com